Gaviscon Advance oral suspension aniseed

Țară: Regatul Unit

Limbă: engleză

Sursă: MHRA (Medicines & Healthcare Products Regulatory Agency)

Ingredient activ:

Sodium alginate; Potassium bicarbonate

Disponibil de la:

Forum Health Products Ltd

INN (nume internaţional):

Sodium alginate; Potassium bicarbonate

Dozare:

100mg/1ml ; 20mg/1ml

Forma farmaceutică:

Oral suspension

Calea de administrare:

Oral

Clasă:

No Controlled Drug Status

Tip de prescriptie medicala:

Valid as a prescribable product

Rezumat produs:

BNF: 01010201; GTIN: 5000158065628 5000158063693

Prospect

GAVISCON ADVANCE ANISEED SUSPENSION.
Sodium alginate and potassium hydrogen carbonate.
READ ALL OF THIS LEAFLET CAREFULLY BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
This medicine is available without prescription. However, you
still need to take this medicine carefully to get the best results
from it.
•
Keep this leaflet. You may need to read it again.
•
Ask your pharmacist if you need more information or advice.
•
YOU MUST CONTACT A DOCTOR IF YOUR SYMPTOMS WORSEN OR DO NOT
IMPROVE AFTER 7 DAYS.
•
If any of the side-effects gets serious,
or if you notice any side-effect not listed in this leaflet, please
tell your doctor or pharmacist.
IN THIS LEAFLET:
1.
What is Gaviscon Advance and what is it used for?
2.
Before taking this medicine.
3.
How to take this medicine.
4.
Possible side effects.
5.
How to store this medicine.
6.
Further information.
1.
WHAT IS THIS MEDICINE AND WHAT IS IT USED FOR?
Gaviscon Advance belongs to a group of medicines called "reflux
suppressants".
This product forms a protective layer that floats on top of the
stomach contents. This layer prevents reflux and keeps the
stomach contents away from the lining of the food pipe to relieve
the symptoms of heartburn and acid indigestion. It can also be
used to relieve the symptoms of conditions such as hiatus hernia
(protrusion of muscle through a muscle wall), reflux oesophagitis
(inflamed foodpipe) and symptoms of hoarseness and other
voice disorders, sore throat and cough associated with reflux.
It can also be taken to control heartburn symptoms which may
occur when taking, or following withdrawal of, medication to
reduce stomach acid such as Proton Pump Inhibitors (PPIs) or
H2 Antagonists.
2.
BEFORE TAKING THIS MEDICINE
DO NOT TAKE GAVISCON ADVANCE:
- If you know you are allergic (hypersensitive) to any of the
ingredients in this product (see ‘Further Information’ for a full
list
of ingredients).
TAKE SPECIAL CARE WITH GAVISCON ADVANCE:
This medicine contains 57.85 mg sodium (main component of
cooking/table salt) in each 5

Caracteristicilor produsului

OBJECT 1
GAVISCON ADVANCE ANISEED ORAL
SUSPENSION
Summary of Product Characteristics Updated 11-Jan-2023 | Forum Health
Products Limited
•
1. Name of the medicinal product
•
2. Qualitative and quantitative composition
•
3. Pharmaceutical form
•
4. Clinical particulars
•
4.1 Therapeutic indications
•
4.2 Posology and method of administration
•
4.3 Contraindications
•
4.4 Special warnings and precautions for use
•
4.5 Interaction with other medicinal products and other forms of
interaction
•
4.6 Fertility, pregnancy and lactation
•
4.7 Effects on ability to drive and use machines
•
4.8 Undesirable effects
•
4.9 Overdose
•
5. Pharmacological properties
•
5.1 Pharmacodynamic properties
•
5.2 Pharmacokinetic properties
•
5.3 Preclinical safety data
•
6. Pharmaceutical particulars
•
6.1 List of excipients
•
6.2 Incompatibilities
•
6.3 Shelf life
•
6.4 Special precautions for storage
•
6.5 Nature and contents of container
•
6.6 Special precautions for disposal and other handling
•
7. Marketing authorisation holder
•
8. Marketing authorisation number(s)
•
9. Date of first authorisation/renewal of the authorisation
•
10. Date of revision of the text
1. Name of the medicinal product
Gaviscon Advance Aniseed Suspension.
2. Qualitative and quantitative composition
ACTIVE SUBSTANCES
MG/10ML
Sodium alginate
1000.0
Potassium bicarbonate
200.0
Excipient(s) with known effect:
Methyl parahydroxybenzoate E218 (20 mg/ 5 ml)
Propyl parahydroxybenzoate E216 (3 mg/ 5 ml).
Sodium (57.85 mg (2.515 mmol)/ 5 ml)
Potassium (39.06 mg/ 5 ml)
Benzyl alcohol* (0.525 mg/ 5 ml)
*present in the fennel flavour
For full list of excipients, see section 6.1.
3. Pharmaceutical form
Oral suspension.
An off-white, viscous suspension.
4. Clinical particulars
4.1 Therapeutic indications
Treatment of symptoms resulting from the reflux of acid, bile and
pepsin into the oesophagus such as acid
regurgitation, heartburn, indigestion (occurring due to the reflux of
stomach contents), for instance, after
gas